INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);UNIVERSITE PARIS DESCARTES;ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP);FONDATION IMAGINE;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQU
The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.